CompletedPhase 1

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

France, Italy, Spain62 participantsStarted 2014-04-11

Plain-language summary

Dose escalation phase of the study : To define the safety profile, maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of regorafenib administered orally as a single agent in a 3-weeks-on/1- week-off schedule in repeating cycles of 28 days in pediatric subjects with solid malignant tumors recurrent or refractory to standard therapy. To characterize the pharmacokinetics (PK) of regorafenib The dose escalation phase of the study has been completed. Expansion phase: To define the safety profile, MTD and the RP2D of regorafenib administered orally in combination with backbone chemotherapy (vincristine and irinotecan) at relapse in pediatric subjects with rhabdomyosarcoma (RMS) and other solid malignant tumors recurrent or refractory to standard therapy.

Who can participate

Age range

6 Months – 18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

Adequate hepatic function defined as:

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Safety: Maximum Tolerated Dose

Timeframe: approximately after 21 months

Safety: Recommended Phase II Dose

Timeframe: approximately after 21 months

Number of participants with Adverse Events

Timeframe: Dose escalation phase:approximately after 21 months; Expansion Phase: approximately after 21 months

AUC(0-24)md based on nominal dosing

Timeframe: Dose escalation phase:Cycle 1 Day 1, Day 15 and Day 21

Trial details

NCT IDNCT02085148

SponsorBayer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-05-05

View on ClinicalTrials.gov More Pediatric Oncology trials

Plain-language summary

What they're measuring

Safety: Maximum Tolerated Dose

Timeframe: approximately after 21 months

Safety: Recommended Phase II Dose

Timeframe: approximately after 21 months

Number of participants with Adverse Events

Timeframe: Dose escalation phase:approximately after 21 months; Expansion Phase: approximately after 21 months

AUC(0-24)md based on nominal dosing

Timeframe: Dose escalation phase:Cycle 1 Day 1, Day 15 and Day 21